Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04662658 · ClinicalTrials.gov registry record · Phase 1

Hyperpolarized Xenon-129 MR Imaging of the Lung

A Phase 1 study of E-Cig Use, sponsored by University of Virginia.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT04662658: Recruiting Phase 1 study of E-Cig Use, sponsored by University of Virginia.

NCT04662658 is a Phase 1 study of E-Cig Use that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 24 participants, below the 149-participant average among 9 other E-Cig Use trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04662658, a Phase 1 study of E-Cig Use, is actively recruiting participants, sponsored by University of Virginia.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Over the past 10 years, electronic cigarettes (e-cigarettes, EC) have been commercialized as a "less harmful" alternative to traditional cigarettes.1,2 However, e-cigarettes are believed to cause pulmonary epithelial, endothelial and vascular dysfunction, and to cause murine phenotypes similar to those of human COPD. Recently, "spiked" vape juice has been linked to severe lung damage. Unfortunately, the effects of e-cigarettes on the human lungs are still poorly understood, especially in healthy young adults. Therefore, establishing the health effects of e-cigarettes in humans is of paramount importance to guide medical and regulatory decision making. Its widespread use and immense popularity among teenagers and young adults have caused major concern given potentially significant addictive and detrimental long-term health effects.

Primary Outcome

To measure the pulmonary physiologic effects of e-cigarette use in young adults with less than a 5 pack-year history of smoking traditional cigarettes.

Conditions Studied

Interventions

  • DRUG Hyperpolarized Xenon -129 MRI

Study Locations (1)

Virginia

  • Snyder Building 480 Ray C. Hunt Drive - Charlottesville

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2020-11-05
Est. Completion 2025-12
Phase Phase 1
University of Virginia

449 total trials

What NCT04662658 shows while recruiting

NCT04662658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 149-participant average among 9 other E-Cig Use trials with a reported enrollment target (84% lower).

The record links to 1 condition, with E-Cig Use appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized Xenon -129 MRI is the first listed.

NCT04662658 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT04662658 about?

NCT04662658 is a clinical study titled "Hyperpolarized Xenon-129 MR Imaging of the Lung". Over the past 10 years, electronic cigarettes (e-cigarettes, EC) have been commercialized as a "less harmful" alternative to traditional cigarettes.1,2 However, e-cigarettes are believed to cause pulmonary epithelial, endothelial and vascular dysfunction, and to cause murine phenotypes similar to th...

What is the current status of trial NCT04662658?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-11-05. Estimated completion is 2025-12.

What conditions does trial NCT04662658 study?

This clinical trial studies the following conditions: E-Cig Use.

What interventions are being tested in trial NCT04662658?

The interventions under investigation include: Hyperpolarized Xenon -129 MRI (DRUG).

Who is sponsoring clinical trial NCT04662658?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04662658 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for E-Cig Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04662658's enrollment target sits among peer trials

24 10th of 9 the lowest of 9 other E-Cig Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other E-Cig Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04662658, the US trial registry maintained by the National Library of Medicine. NCT04662658 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.